-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Akebia Therapeutics at Buy, Announces Price Target of $8

Benzinga·06/04/2025 11:20:49
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield assumes Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $8.